

# Nicaragua

## Tuberculosis profile

Population 2015

6.1 million

| Estimates of TB burden*, 2015 | Number (thousands)  | Rate (per 100 000 population) |
|-------------------------------|---------------------|-------------------------------|
| Mortality (excludes HIV+TB)   | 0.15 (0.12–0.19)    | 2.5 (1.9–3.1)                 |
| Mortality (HIV+TB only)       | 0.028 (<0.01–0.086) | 0.46 (0.04–1.4)               |
| Incidence (includes HIV+TB)   | 3.1 (2.4–3.9)       | 51 (39–64)                    |
| Incidence (HIV+TB only)       | 0.15 (0.12–0.2)     | 2.5 (1.9–3.2)                 |
| Incidence (MDR/RR-TB)**       | 0.078 (0.034–0.12)  | 1.3 (0.56–2)                  |

Estimated TB incidence by age and sex (thousands)\*, 2015

|         | 0-14 years        | > 14 years     | Total          |
|---------|-------------------|----------------|----------------|
| Females | 0.15 (0.085–0.22) | 1.1 (0.66–1.5) | 1.2 (0.75–1.7) |
| Males   | 0.14 (0.093–0.19) | 1.7 (1.3–2.1)  | 1.8 (1.4–2.3)  |
| Total   | 0.3 (0.21–0.38)   | 2.8 (2.4–3.2)  | 3.1 (2.4–3.9)  |

TB case notifications, 2015

|  |       |
|--|-------|
| Total cases notified                                   | 2 546 |
| Total new and relapse                                  | 2 465 |
| - % tested with rapid diagnostics at time of diagnosis |       |
| - % with known HIV status                              | 94%   |
| - % pulmonary  | 87%   |
| - % bacteriologically confirmed among pulmonary        | 79%   |

Universal health coverage and social protection

|  |                  |
|--|------------------|
| TB treatment coverage (notified/estimated incidence), 2015             | 80% (64–100)     |
| TB patients facing catastrophic total costs                            |                  |
| TB case fatality ratio (estimated mortality/estimated incidence), 2015 | 0.06 (0.04–0.09) |

TB/HIV care in new and relapse TB patients, 2015

|   | Number | (%) |
|---|--------|-----|
| Patients with known HIV-status who are HIV-positive | 117    | 5%  |
| - on antiretroviral therapy                         | 115    | 98% |

| Drug-resistant TB care, 2015                                | New cases     | Previously treated cases | Total number*** |
|---|---------------|--------------------------|-----------------|
| Estimated MDR/RR-TB cases among notified pulmonary TB cases |               |                          | 45 (15–74)      |
| Estimated % of TB cases with MDR/RR-TB                      | 0.94% (0–2.3) | 12% (7.3–18)             |                 |
| % notified tested for rifampicin resistance                 | 19%           | 121%                     | 709             |
| MDR/RR-TB cases tested for resistance to second-line drugs  |               |                          | 0               |
| Laboratory-confirmed cases                                  |               | MDR/RR-TB: 36, XDR-TB: 2 |                 |
| Patients started on treatment ****                          |               | MDR/RR-TB: 29, XDR-TB: 1 |                 |

| Treatment success rate and cohort size                          | Success | Cohort |
|---|---------|--------|
| New and relapse cases registered in 2014                        | 85%     | 1 577  |
| Previously treated cases, excluding relapse, registered in 2014 | 78%     | 77     |
| HIV-positive TB cases, all types, registered in 2014            |         |        |
| MDR/RR-TB cases started on second-line treatment in 2013        | 78%     | 9      |
| XDR-TB cases started on second-line treatment in 2013           |         | 0      |

TB preventive treatment, 2015

|   |             |
|---|-------------|
| % of HIV-positive people (newly enrolled in care) on preventive treatment                                   | 6%          |
| % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment | 44% (41–48) |

TB financing, 2016

|   |     |
|---|-----|
| National TB budget (US\$ millions)                            | 9.5 |
| Funding source: 54% domestic, 26% international, 20% unfunded |     |


\* Ranges represent uncertainty intervals

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history


\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




Incidence  
Notified (new and relapse)  
Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



New and relapse  
Retreatment, excluding relapse  
HIV-positive MDR/RR-TB XDR-TB

Total budget (US\$ millions)

